MedTrace Logo

Clinical Trial in Patients Diagnosed With Immune Thrombocytopenic Purpura

NCT00699140 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2016-02-08

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine whether IGIV3I Grifols 10% is effective in the treatment of immune thrombocytopenic purpura.

Conditions

  • Immune (Idiopathic) Thrombocytopenic Purpura

Interventions

BIOLOGICAL

IGIV3I Grifols

Immune Globulin Intravenous (Human)

Sponsors & Collaborators

  • Instituto Grifols, S.A.

    lead INDUSTRY

Principal Investigators

  • María Teresa Álvarez, MD · Hospital General Universitario La Paz

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
82 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-02-29
Primary Completion
2013-12-31
Completion
2013-12-31

Countries

  • Russia
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00699140 on ClinicalTrials.gov